We found that combinatorial CCR2+HSCs plus anti-PD-1 leads to increased median survival and long-term survivors in preclinical brain tumor models (glioblastoma and medulloblastoma) that are completely refractory to PD-1 treatment alone. Here, CCR2 is linked to brain neoplasm.